

IMPACT FACTOR 3.4

Indexed in: PubMed



an Open Access Journal by MDPI

Inflammatory Bowel Disease: Advancement in Diagnosis and Medical Management

Guest Editors:

Dr. Marianna Lucafò

Institute for Maternal and Child Health -IRCCS "Burlo Garofolo", Trieste, Italy

Prof. Dr. Giuliana Decorti

1. Institute for Maternal and Child Health -IRCCS "Burlo Garofolo", Trieste, Italy 2. Department of Medical, Surgical and Health Sciences,

University of Trieste, Trieste, Italy

Deadline for manuscript submissions:

closed (15 June 2023)

Message from the Guest Editors

The diagnosis and monitoring of IBD patients require a personalized evaluation to guide treatment decisions. To date, the therapeutic approach is mainly aimed at the treatment and control of inflammation, through drugs capable of inducing and maintaining remission. Given the lack of clinical predictors, patients are still treated by using a "one size fits all" approach. Therefore, there is a growing need to offer a personalized approach for each individual patient combining early action with proactive management through the use of precision medicine tools.

This Special Issue will include studies on specific markers and novel pathways involved in IBD pathogenesis that may be used for an early diagnosis and/or for personalized precision medicine. Recent advances on the use of patient-derived innovative cellular models, such as organoids, to study the functional role of specific new therapeutic targets and to screen novel drugs with a direct action on intestinal epithelial cells to shift towards an individualized medicine approach in IBD will be also encouraged.

Original research articles and reviews focusing on these topics will be included in this Special Issue.







IMPACT FACTOR 3.4





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

 Novant Health Cancer Institute, Winston-Salem, NC 27103, USA
Division of Hematologic Malignancies and Cellular Therapy, Duke University,

Durham, NC 27710, USA

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. JPM publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). JPM is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank: JCR - Q2 (*Medicine, General & Internal*) CiteScore - Q2 (*Medicine (miscellaneous*))

Contact Us